Q&A with Seth Karol, MD: Risk Factors for Bone Toxicity for Patients with ALL

Video

Seth Karol, MD, St. Jude's Children's Research Center discussed several ways in which he and his colleagues intensified therapy over the years and referred to a key toxicity that had emerged from the two drugs they used.

Seth Karol, MD, St. Jude's Children's Research Center discussed several ways in which he and his colleagues intensified therapy over the years and referred to a key toxicity that had emerged from the two drugs they used.

Karol understands further studies are necessary to ensure their methods of reducing risks don't affect the success of curing diseases.

Related Videos
Ankeet Bhatt, MD, MBA | Credit: X.com
Sara Saberi, MD | Credit: University of Michigan
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Veraprapas Kittipibul, MD | Credit: X.com
Addressing HS Risks at the Genetic Level, with Kai Li, BSc
Building a Psoriasis Knockout Regimen Around Risankizumab, with Andrew Blauvelt, MD, MBA
Joel Gelfand, MD, MSCE: Phototherapy Utility in Psoriasis
© 2024 MJH Life Sciences

All rights reserved.